Thus, the pooled analyses provide a more
robust estimate of the treatment benefi t for rolapitant
across acute, delayed, and overall phases, with more
complete responses, complete protection, no emesis, no
nausea, no clinically signifi cant nausea, and delayed
time-to-fi rst emesis or use of rescue medication,
compared with active control